Berlin - Delayed Quote ? EUR IRLAB Therapeutics AB (6IRA.BE) Follow Compare 1.0900 +0.0600 (+5.83%) At close: October 18 at 7:35 PM GMT+2 All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations IRLAB Presents at Redeye Neurology Theme Event GOTHENBURG, SE / ACCESSWIRE / October 18, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, October 18, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's ... ACCESSWIRE ? 2 days ago 6IRA.F IRLAB Receives Milestone Payment of USD 2.5 million in Conjunction with First Dosing in a Phase I Study with IRL757 in Healthy Older Adults GOTHENBURG, SWEDEN / ACCESSWIRE / October 8, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced that dosing ... ACCESSWIRE ? 12 days ago 6IRA.F Positive Data from the First Part of IRLAB's Phase I Study with the Drug Candidate IRL757 GOTHENBURG, SE / ACCESSWIRE / October 3, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, October 3 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A) - a company discovering and developing novel treatments for Parkinson's ... ACCESSWIRE ? 17 days ago 6IRA.F IRLAB has Enrolled the Last Patient in the Phase IIb Study of Pirepemat GOTHENBURG, SWEDEN / ACCESSWIRE / September 30, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, September 30, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company that discovers and develops new treatments for Parkinson's ... ACCESSWIRE ? 20 days ago 6IRA.F IRLAB Presents at the International Congress of Parkinson's Disease and Movement Disorders(R)(MDS) 2024 GOTHENBURG, SE / ACCESSWIRE / September 25, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, September 25, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company that discovers and develops new treatments for Parkinson's ... ACCESSWIRE ? 25 days ago 6IRA.F IRLAB Granted Additional Patent for its Drug Candidate Pirepemat Expanding the Patent Protection in the US GOTHENBURG, SE / ACCESSWIRE / September 18, 2024 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA) Gothenburg, Sweden, September 18, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson's ... ACCESSWIRE ? last month 6IRA.F IRLAB Participates in Pareto Securities' 15th Annual Healthcare Conference GOTHENBURG, SE / ACCESSWIRE / September 13, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, September 13, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's ... ACCESSWIRE ? last month 6IRA.F IRLAB Participates in the Event Investing in Life Science: From Seed to Success GOTHENBURG, SE / ACCESSWIRE / September 06, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, September 6, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's ... ACCESSWIRE ? last month 6IRA.F IRLAB is Granted Additional Patent for Drug Candidate Mesdopetam that Expands its Patent Protection GOTHENBURG, SWEDEN / ACCESSWIRE / September 4, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, September 4, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson's ... ACCESSWIRE ? last month 6IRA.F IRLAB Publishes Interim Report for the Period January-June 2024 GOTHENBURG, SWEDEN / ACCESSWIRE / July 10, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, July 10, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's ... ACCESSWIRE ? 3 months ago 6IRA.F IRLAB: Invitation to the Interim Report for Q2 2024 Presentation and Webcast GOTHENBURG, SE / ACCESSWIRE / July 08, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, July 8, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, ... ACCESSWIRE ? 3 months ago 6IRA.F IRLAB's Phase IIb Study of Pirepemat Can Proceed as Planned after Positive Opinion from External Safety Committee GOTHENBURG, SWEDEN / ACCESSWIRE / July 2, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, July 2, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's ... ACCESSWIRE ? 3 months ago 6IRA.F IRLAB Participates in Stora Aktiedagarna GOTHENBURG, SWEDEN / ACCESSWIRE / June 11, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, June 11, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson's ... ACCESSWIRE ? 4 months ago 6IRA.F IRLAB Presents at Redeye Growth Day 30 May GOTHENBURG, SE / ACCESSWIRE / May 28, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden. May 28, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A) - a company discovering and developing novel treatments for Parkinson's disease ... ACCESSWIRE ? 4 months ago 6IRA.F IRLAB Appoints Kristina Torfg?rd as New CEO GOTHENBURG, SE / ACCESSWIRE / May 27, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden. May 27, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A) - a company discovering and developing novel treatments for Parkinson's disease ... ACCESSWIRE ? 4 months ago 6IRA.F IRLAB Strengthens its Liquidity by Drawing SEK 25 million on a Previously Secured Loan Facility GOTHENBURG, SE / ACCESSWIRE / May 23, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, May 23, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, ... ACCESSWIRE ? 4 months ago 6IRA.F Report from the Annual General Meeting 2024 of IRLAB Therapeutics AB GOTHENBURG, SWEDEN / ACCESSWIRE / May 22, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Today, on Wednesday May 22, 2024, IRLAB Therapeutics AB held its Annual General Meeting. The following main resolutions were made upon at the Annual General ... ACCESSWIRE ? 4 months ago 6IRA.F IRLAB has Administered the First Dose in a Phase I Clinical Trial with the Drug Candidate IRL757 GOTHENBURG, SWEDEN / ACCESSWIRE / May 22, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, May 22, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson's ... ACCESSWIRE ? 4 months ago 6IRA.F IRLAB Broadcasts the Annual General Meeting Live GOTHENBURG, SWEDEN / ACCESSWIRE / May 22, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, May 22, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson's ... ACCESSWIRE ? 4 months ago 6IRA.F IRLAB Presents at ABGSC Investor Days GOTHENBURG, SWEDEN / ACCESSWIRE / May 21, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, May 21, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson's ... ACCESSWIRE ? 4 months ago 6IRA.F Performance Overview Trailing total returns as of 10/18/2024, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index Return 6IRA.BE OMX Stockholm 30 Index YTD +59.82% +8.18% 1-Year +79.87% +19.43% 3-Year -76.23% +12.07%
